Abstract | INTRODUCTION:
Folliculitis is the most common side effect of epidermal growth factor receptor (EGFR) inhibitors (EGFRIs). It is often apparent, altering patients' quality of life and possibly impacting compliance. Variations in terms of the treatment-related incidence and intensity have not been fully elucidated. Tetracyclines have been recommended for the prophylaxis and treatment of folliculitis but their efficacy is yet to be established. MATERIALS AND METHODS: We carried out two systematic literature reviews. The first assessed the preventive and curative efficacy of tetracyclines. The second assessed the incidence of grade 3-4 folliculitis in the main clinical studies published. RESULTS: CONCLUSION: Unless contraindicated, a tetracycline should be routinely prescribed prophylactically for patients treated with an EGFRI (level of evidence, B2). In curative therapy, the level of evidence for tetracycline efficacy is low (level of evidence, D). The incidence of grade 3-4 folliculitis induced by EGFRIs appears to be lower with gefitinib.
|
Authors | Jean-Baptiste Bachet, Lucie Peuvrel, Claude Bachmeyer, Ziad Reguiai, Pierre A Gourraud, Olivier Bouché, Marc Ychou, Rene J Bensadoun, Brigitte Dreno, Thierry André |
Journal | The oncologist
(Oncologist)
Vol. 17
Issue 4
Pg. 555-68
( 2012)
ISSN: 1549-490X [Electronic] England |
PMID | 22426526
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Chemical References |
- Protein Kinase Inhibitors
- Tetracyclines
- ErbB Receptors
|
Topics |
- ErbB Receptors
(antagonists & inhibitors, metabolism)
- Folliculitis
(chemically induced, drug therapy, pathology, prevention & control)
- Humans
- Incidence
- Protein Kinase Inhibitors
(adverse effects)
- Randomized Controlled Trials as Topic
- Tetracyclines
(therapeutic use)
|